Beam Therapeutics/BEAM

$24.62

3.48%
-
1D1W1MYTD1YMAX

About Beam Therapeutics

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Ticker

BEAM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Evans

Employees

436

Headquarters

Cambridge, United States
Website
beamtx.com

BEAM Metrics

BasicAdvanced
$2B
Market cap
-
P/E ratio
-$1.74
EPS
1.88
Beta
-
Dividend rate
$2B
1.88498
$49.50
$16.95
1.5M
5.991
-10.01%
-16.09%
-11.79%
5.499
2.172
2.172
370.57%
60.91%
2,406%

What the Analysts think about BEAM

Analyst Ratings

Majority rating from 15 analysts.
Buy

Price Targets

Average projection from 12 analysts.
97.68% upside
High $78.00
Low $23.00
$24.62
Current price
$48.67
Average price target

BEAM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,332.43% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.4M
-97.66%
Net income
-$99M
-169.1%
Profit margin
-1,332.43%
-3,051.77%

BEAM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.63%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.08
-$1.22
$1.73
-$1.21
-
Expected
-$1.42
-$1.36
-$1.01
-$1.42
-$1.14
Surprise
-24.19%
-10.4%
-271.08%
-14.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Beam Therapeutics stock?

Beam Therapeutics (BEAM) has a market cap of $2B as of May 18, 2024.

What is the P/E ratio for Beam Therapeutics stock?

The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of May 18, 2024.

Does Beam Therapeutics stock pay dividends?

No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Beam Therapeutics dividend payment date?

Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.

What is the beta indicator for Beam Therapeutics?

Beam Therapeutics (BEAM) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Beam Therapeutics stock price target?

The target price for Beam Therapeutics (BEAM) stock is $48.67, which is 97.68% above the current price of $24.62. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Beam Therapeutics stock

Buy or sell Beam Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing